Jeffrey Kindler, Pfizer’s Chief Executive Officer has announced a 
turnaround in its leadership positions to re-arrange the drug company, struggling with augmented competition and the loss of exclusivity rights. Two key functions, Research and Finance, are the targetted two blocks. 57-year-old John LaMattina, the research and development chief of the company for a long time, and 45-year-old Alan Levin, the short-time chief financial officer will be retiring soon as a new replacement (rather successor) is found out. All these steps are a consequence of Kindler’s strategies to ‘transform’ Pfizer into a leaner, more productive company.
turnaround in its leadership positions to re-arrange the drug company, struggling with augmented competition and the loss of exclusivity rights. Two key functions, Research and Finance, are the targetted two blocks. 57-year-old John LaMattina, the research and development chief of the company for a long time, and 45-year-old Alan Levin, the short-time chief financial officer will be retiring soon as a new replacement (rather successor) is found out. All these steps are a consequence of Kindler’s strategies to ‘transform’ Pfizer into a leaner, more productive company.For Complete IIPM Article, Click on IIPM Article
Source: IIPM Editorial, 2006
An IIPM and Management Guru Prof. Arindam Chaudhuri's Initiative
Source: IIPM Editorial, 2006
An IIPM and Management Guru Prof. Arindam Chaudhuri's Initiative
